Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Arvinas logo — Leading the way in targeted protein degradation therapeutics

Arvinas

Leading the way in targeted protein degradation therapeutics

Founded 2013 United States New Haven, United States 305 employees Total: $585.85M Biotechnology, Health Care +2

General Information

Company Name Arvinas
Founded Year 2013
Location United States New Haven, United States
Founders / Decision Makers
Team member Team member Team member
Employees 305
Industries Biotechnology, Health Care, Health and Wellness +1
Social

BounceWatch is an independent company data service, not affiliated with Arvinas. To contact Arvinas, visit arvinas.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Arvinas compare?

A PDF of Arvinas and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Arvinas soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

Recorded by Bounce Watch from public sources. Every entry below carries the date we observed it, and when we have not looked recently the page says so rather than leaving silence to imply nothing happened.

Event Participation Oct 07, 2026

Arvinas shared Oculomotor and Biomarker Data from its Phase 1 clinical trial of its #PROTAC LRRK2 degrader in Parkinson’s Disease at the 2026 International Congress of Parkinson’s Disease and Movem…

Arvinas a competitor of yours? Have our desk watch it

About Arvinas

Arvinas is a clinical-stage biopharmaceutical company founded in 2013 and headquartered in the United States. The company is committed to developing targeted protein degradation therapeutics with the aim of improving the lives of patients suffering from debilitating and life-threatening diseases. Their proprietary PROTAC® Discovery Engine platform enables the engineering of PROTAC® targeted protein degraders, which leverage the body’s natural protein disposal system to selectively degrade and remove disease-causing proteins. Arvinas boasts a robust preclinical pipeline of PROTAC® protein degraders targeting validated and “undruggable” proteins and has two clinical-stage programs: ARV-110 for metastatic castrate-resistant prostate cancer and ARV-471 for locally advanced or metastatic ER+\/HER2- breast cancer. One of the notable achievements of Arvinas is the $350.00M Post-IPO Equity investment received on 27 November 2023. The investment was made by prominent firms such as RA Capital Management, Boxer Capital, ArrowMark Partners, BB Biotech Ventures, EcoR1 Capital, RTW Investments, Great Point Partners, Citadel Global Equities, Surveyor Capital, and Avidity Partners. In summary, Arvinas stands at the forefront of biotechnology and pharmaceutical industries, offering innovative therapies and attracting substantial investments to support its groundbreaking research and development efforts. For more information, visit www.arvinas.com.

Business keywords: biopharmaceutical, protein degradation, therapeutics, clinical-stage, disease treatment, PROTAC® Discovery Engine platform, proteolysis targeting chimeras, metastatic castrate-resistant prostate cancer, locally advanced breast cancer, metastatic ER+/HER2- breast cancer, drug discovery, autoimmune diseases, rare diseases, cancer therapy, preclinical pipeline

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Private Placement VC $350.00M -
01 Nov 2023
IPO $120.00M -
01 Sep 2018
Series C $55.00M 9
RA Capital Management 5AM Ventures OrbiMed
RA Capital Management, 5AM Ventures +7
01 Apr 2018
Spinout Undisclosed 1
University Ventures
University Ventures
01 Jan 2017
Series B $41.60M 5
New Leaf Venture Partners RA Capital Management 5AM Ventures
New Leaf Venture Partners, RA Capital Management +3
01 Oct 2015
Series A $19.25M 4
Connecticut Innovations 5AM Ventures Elm Street Ventures
Connecticut Innovations, 5AM Ventures +2
01 Sep 2013

Latest News

View All
Alentis doubles down on Claudin1 | ApexOnco - Clinical Trials news and analysis — Oncologypipeline.com
Alentis doubles down on Claudin1 | ApexOnco - Clinical Trials news and analysis
Oncologypipeline.com Sep 25, 2025

Arvinas Alternatives & Competitors

View All Alternatives
Arvinas vs
Kangpu Biopharmaceuticals, Ltd.
Kangpu Biopharmaceuticals, Ltd. China

Kangpu Biopharmaceuticals, Ltd. is a clinical-stage company focused on the discovery and development...

Series B
14 employees
Biopharma, Health Care
Compare Arvinas vs Kangpu Biopharmaceuticals, Ltd.
Arvinas vs
Precigen
Precigen United States

Precigen (Nasdaq: PGEN) is a biopharmaceutical company advancing the next generation of gene and cel...

Post-IPO Equity
152 employees
Biotechnology, Health and Wellness
Compare Arvinas vs Precigen
Arvinas vs
Captor Therapeutics SA
Captor Therapeutics SA Poland

Captor Therapeutics aims to treat cancer, infections, and diseases by targeting the difficult-to-dru...

IPO
85 employees
Biopharma, Biotechnology
Also compare with: Arvinas vs Cullgen Inc. Cullgen Inc. View all alternatives

FAQ About Arvinas

Leading the way in targeted protein degradation therapeutics
Arvinas was founded in 2013.
Arvinas is headquartered in New Haven, United States.
Arvinas operates in Biotechnology, Health Care, Health and Wellness and Pharmaceutical. Its work centres on biopharmaceutical, protein degradation, therapeutics and clinical-stage.
Arvinas has approximately 305 employees.
Arvinas has completed 6 funding rounds, raising a total of $585.85M.
Top alternatives and competitors to Arvinas include Kangpu Biopharmaceuticals, Ltd., Precigen, Captor Therapeutics SA, Orum Therapeutics, Forma Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Arvinas and Kangpu Biopharmaceuticals, Ltd. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Arvinas, https://bouncewatch.com/company/arvinas, updated 30 June 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout